Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorNieto-Fontarigo, Juan José
dc.contributor.authorSalgado, Francisco J
dc.contributor.authorSan-José, María Esther
dc.contributor.authorCruz Carmona, Mª Jesús
dc.contributor.authorValdés, Luis
dc.contributor.authorPérez-Díaz, Amparo
dc.date.accessioned2019-06-28T11:05:22Z
dc.date.available2019-06-28T11:05:22Z
dc.date.issued2019-05-17
dc.identifier.citationNieto-Fontarigo JJ, Salgado FJ, San-José ME, Cruz MJ, Valdés L, Pérez-Díaz A, et al. Expansion of different subpopulations of CD26−/low T cells in allergic and non-allergic asthmatics. Sci Rep. 2019;9(1):7556.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11351/4162
dc.descriptionAsthma; Allergy; CD26
dc.description.abstractCD26 displays variable levels between effector (TH17 ≫ TH1 > TH2 > Treg) and naïve/memory (memory > naïve) CD4+ T lymphocytes. Besides, IL-6/IL-6R is associated with TH17-differentiation and asthma severity. Allergic/atopic asthma (AA) is dominated by TH2 responses, while TH17 immunity might either modulate the TH2-dependent inflammation in AA or be an important mechanism boosting non-allergic asthma (NAA). Therefore, in this work we have compared the expression of CD26 and CD126 (IL-6Rα) in lymphocytes from different groups of donors: allergic (AA) and non-allergic (NAA) asthma, rhinitis, and healthy subjects. For this purpose, flow cytometry, haematological/biochemical, and in vitro proliferation assays were performed. Our results show a strong CD26-CD126 correlation and an over-representation of CD26- subsets with a highly-differentiated effector phenotype in AA (CD4+CD26-/low T cells) and NAA (CD4-CD26- γδ-T cells). In addition, we found that circulating levels of CD26 (sCD26) were reduced in both AA and NAA, while loss of CD126 expression on different leukocytes correlated with higher disease severity. Finally, selective inhibition of CD26-mRNA translation led to enhanced T cell proliferation in vitro. These findings support that CD26 down-modulation could play a role in facilitating the expansion of highly-differentiated effector T cell subsets in asthma.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesScientific Reports;9(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAsma - Aspectes immunològics
dc.subjectCèl·lules T - Immunologia
dc.subjectAntigen CD26
dc.subject.meshAsthma
dc.subject.meshCD4-Positive T-Lymphocytes
dc.subject.mesh/immunology
dc.subject.meshDipeptidyl Peptidase 4
dc.titleExpansion of different subpopulations of CD26−/low T cells in allergic and non-allergic asthmatics
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41598-019-43622-8
dc.subject.decsasma
dc.subject.decslinfocitos T CD4-positivos
dc.subject.decs/inmunología
dc.subject.decsdipeptidil peptidasa-4
dc.relation.publishversionhttps://www.nature.com/articles/s41598-019-43622-8
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Nieto-Fontarigo JJ, Salgado FJ] Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain. [San-José ME] Clinical Analysis Service, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. [Cruz MJ] Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centre de recerca en xarxa de malalties respiratòries-CIBERES, Barcelona, Spain. [Valdés L] Department of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Department of Respiratory Medicine, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Pérez-Díaz A] Drug Screening Platform/Biopharma Research Group, Molecular Medicine and Chronic Diseases Research Centre (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
dc.identifier.pmid31101830
dc.identifier.wosWOS:000468171100051
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record